Integrating Immune Checkpoint Inhibitors Into the Clinic for Patients with Advanced Bladder Cancer

In this downloadable slideset, Andrea B. Apolo, MD, addresses the management of adverse events associated with immune checkpoint inhibitors and highlights new data for treatment options after immune checkpoint inhibitors for optimal outcomes in patients with advanced bladder cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 2.26 MB
Released: February 14, 2018

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Merck & Co., Inc.
Seattle Genetics
Astellas

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue